18.42
-1.14(-5.83%)
Currency In USD
| Previous Close | 19.56 |
| Open | 19.37 |
| Day High | 19.9 |
| Day Low | 18.37 |
| 52-Week High | 19.9 |
| 52-Week Low | 5.2 |
| Volume | 121,389 |
| Average Volume | 122,230 |
| Market Cap | 156.82M |
| PE | -0.71 |
| EPS | -26 |
| Moving Average 50 Days | 12.4 |
| Moving Average 200 Days | 9.71 |
| Change | -1.14 |
If you invested $1000 in Sutro Biopharma, Inc. (STRO) since IPO date, it would be worth $121.18 as of February 21, 2026 at a share price of $18.42. Whereas If you bought $1000 worth of Sutro Biopharma, Inc. (STRO) shares 5 years ago, it would be worth $80.47 as of February 21, 2026 at a share price of $18.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
GlobeNewswire Inc.
Feb 10, 2026 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire Inc.
Dec 17, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced